home
enabling drug discovery in the ubiquitin field since 2010
Access to well-defined and advanced ubiquitin research tools and ubiquitin-like research tools is of paramount importance for drug development, fundamental research and structural studies. Since we founded our company in 2010, our ubiquitin and ubiquitin-like research tools have been well-recognised by both Pharma & Academia. Many leading laboratories in the field worldwide use our innovative and custom reagents. We also collaborate with outstanding scientists on research projects to further our insights in this growing field. We are proud that our joint efforts regularly result in publications in high-ranking journals. You can find examples in "our publications" section below this page. For an extensive list of our publications, please visit our resource download center.
Please explore how our ubiquitin research tools expedite the three stages of early drug discovery, i.e. target - lead - lead on target, by clicking on the buttons below:
target
Identify and validate your target using our probes
hit-to-lead
compound screening using our assay reagents
lead on target
lead on target validation and lead optimization
target
Identify and validate your target using UbiQ Probes.
lead
Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.
lead on target
Our reagents enable you in lead on target validation and lead optimization.
catalogue ubiquitin reagents
In our laboratory at the Amsterdam Science Park, UbiQ develops, manufactures, and commercializes research tools such as ubiquitinated peptides, activity-based probes, and activity assay reagents. In addition to ubiquitin, we also make ubiquitin-like variants (SUMO, ISG15, NEDD8, etc.) of our reagents.
Please note our research tools are “For laboratory research use only, not for use in animals and humans".
custom ubiquitin reagents
With our UbiQ technologies we can synthesize in a site-selective manner ubiquitinated peptides and reagents that are not readily available through biological approaches. Next to our catalogue reagents, we offer a tailored chemical approach to producing specific ubiquitinated conjugates. This custom ubiquitin synthesis approach allows researchers to design unique ubiquitinated peptides and ubiquitin reagents.
news
Poster prize award at the GRK2243 Symposium Understanding Ubiquitylation
We congratulate Dr Cara Ellison from the University of Oxford with the Poster Prize award at the GRK2243 Symposium Understanding Ubiquitylation: From Molecular Mechanisms to Disease 2025, in Würzburg (Germany).
Live cell delivery of ubiquitin reagents by bead loading
We present a new protocol for intracellular delivery of our reagents (Figure 1). In protocol P010, (also in our resource download center), we outline a...
First Poster Prize award at the EMBO ubiquitin conference
We congratulate Dr Jason Collins from the National Institute of Dental and Craniofacial Research / NIH (Bethesda, USA) with the First Poster Prize award at the 2024 EMBO ubiquitin conference in Cavtat.
Jason...Poster Prize awardees at the Biochemical Society conference in Edinburgh
We congratulate the Poster Prize awardees at last week's Deubiquitylases and Ubl-proteases conference of the Biochemical Society: well done to Benjamin Foster, Joana Gomes Neto, Alicia Cordova-Perez and Kim Wendrich.
June 19 – 21, 2023, Edinburgh, UK
Launch of four new activity-based probes for deubiquitinating enzymes
We present four new HA-tagged activity-based probes for deubiquitinating enzymes (DUBs). The HA peptide sequence (YPYDVPDYA) allows for the sensitive identification or purification of DUBs by anti-HA antibodies and/or anti-HA-agarose. The HA tag is separated from...
where to meet us
Australian Ubiquitin Summit 2025
November 20 - 23, 2025 in Lorne, Australia
Lorne Ubiquitin - The Australia Ubiquitin Summit, 2025
Contact: Farid El Oualid (CSO, attending the conference) and Alfred Nijkerk (CEO, sponsorship)
Innovation For Health 2025
April 3, 2025, Rotterdam, the Netherlands
Innovation For Health 2025
Contact: Alfred Nijkerk (CEO)
